TTOO vs. PYPD, LYRA, NEPH, PAVM, MHUA, IINN, ICU, MDAI, NMTC, and FEMY
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include PolyPid (PYPD), Lyra Therapeutics (LYRA), Nephros (NEPH), PAVmed (PAVM), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), SeaStar Medical (ICU), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), and Femasys (FEMY). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
In the previous week, T2 Biosystems had 4 more articles in the media than PolyPid. MarketBeat recorded 5 mentions for T2 Biosystems and 1 mentions for PolyPid. T2 Biosystems' average media sentiment score of 0.42 beat PolyPid's score of 0.31 indicating that PolyPid is being referred to more favorably in the media.
PolyPid has higher earnings, but lower revenue than T2 Biosystems.
PolyPid has a net margin of 0.00% compared to PolyPid's net margin of -636.09%. PolyPid's return on equity of 0.00% beat T2 Biosystems' return on equity.
26.5% of PolyPid shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 0.1% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
PolyPid has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.
PolyPid presently has a consensus price target of $14.00, suggesting a potential upside of 224.45%. T2 Biosystems has a consensus price target of $3.00, suggesting a potential downside of 46.81%. Given T2 Biosystems' stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than T2 Biosystems.
T2 Biosystems received 383 more outperform votes than PolyPid when rated by MarketBeat users. However, 74.19% of users gave PolyPid an outperform vote while only 64.65% of users gave T2 Biosystems an outperform vote.
Summary
PolyPid beats T2 Biosystems on 11 of the 15 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
